Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Sponsor
Zhujiang Hospital
Study ID
NCT05638451
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.

Key Dates

First listed
Dec 6, 2022
Start date
May 1, 2023
Status verified
Jun 2023
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sintilimab and Bevacizumab and Temozolomide
    single arm study

Primary Outcome Measure

Progression free survival rate at 6 months [ Time Frame: Up to two years ]

Central Contacts

Related Studies